Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3970461"]PUTTING PATIENTS 1st ALWAYS A PRIORITY AT NOVARTIS !</p><p><br /></p><p>Jan. 19, 2006 -- The FDA has approved the "black box" warning prescription eczema drug will carry.</p><p><br /></p><p>The FDA announced in March 2005 that Novartis topical eczema drug -- Elidel cream -- would get a "black box" warning about a possible cancer risk. A "black box" warning is the FDA's strongest warning</p><p>An FDA committee had recommended the warning in February 2005. Now, the FDA has approved the warning's content.</p><p>The warning states that there have been reports of cancer (for example, skin and lymphoma) in patients who had been receiving the drug</p><p><br /></p><p><br /></p><p>FDA Issues Health Advisory Regarding the Safety of Lamisil® Tablets to Treat Fungal Nail Infections</p><p> The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to announce significant safety-related updates to the labeling Of Novartis Lamisil® (terbinafine hydrochloride) tablets. Lamisil® is used to treat nail (onychomycosis), skin and other systemic fungal infections. </p><p>The purpose of today's FDA Public Health Advisory is to alert healthcare professionals to serious risks associated with the use of Lamisil®. </p><p>Lamisil® has been associated with serious liver problems resulting in liver failure and death. As of April 2001, FDA has received and reviewed 16 possible Lamisil®-associated cases of liver failure, including 11 deaths and two liver transplantations[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3970461"]PUTTING PATIENTS 1st ALWAYS A PRIORITY AT NOVARTIS ! Jan. 19, 2006 -- The FDA has approved the "black box" warning prescription eczema drug will carry. The FDA announced in March 2005 that Novartis topical eczema drug -- Elidel cream -- would get a "black box" warning about a possible cancer risk. A "black box" warning is the FDA's strongest warning An FDA committee had recommended the warning in February 2005. Now, the FDA has approved the warning's content. The warning states that there have been reports of cancer (for example, skin and lymphoma) in patients who had been receiving the drug FDA Issues Health Advisory Regarding the Safety of Lamisil® Tablets to Treat Fungal Nail Infections The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to announce significant safety-related updates to the labeling Of Novartis Lamisil® (terbinafine hydrochloride) tablets. Lamisil® is used to treat nail (onychomycosis), skin and other systemic fungal infections. The purpose of today's FDA Public Health Advisory is to alert healthcare professionals to serious risks associated with the use of Lamisil®. Lamisil® has been associated with serious liver problems resulting in liver failure and death. As of April 2001, FDA has received and reviewed 16 possible Lamisil®-associated cases of liver failure, including 11 deaths and two liver transplantations[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>